Small-molecule compounds inhibiting S-phase kinase-associated protein 2: A review

Jing Jia,Rui Li, Junyuan Sun, Jinfeng Yang, Zhihao Hong,Weiguo Lu,Zhenyu Jia

Frontiers in pharmacology(2023)

引用 1|浏览4
暂无评分
摘要
S-phase kinase-associated protein 2 (Skp2) is a substrate-specific adaptor in Skp1-CUL1-ROC1-F-box E3 ubiquitin ligases and widely regarded as an oncogene. Therefore, Skp2 has remained as an active anticancer research topic since its discovery. Accordingly, the structure of Skp2 has been solved and numerous Skp2 inhibiting compounds have been identified. In this review, we would describe the structural features of Skp2, introduce the ubiquitination function of SCFSkp2, and summarize the diverse natural and synthetic Skp2 inhibiting compounds reported to date. The IC50 data of the Skp2 inhibitors or inhibiting compounds in various kinds of tumors at cellular levels implied that the cancer type, stage and pathological mechanisms should be taken into consideration when selecting Skp2-inhibiting compound for cancer treatment.
更多
查看译文
关键词
cancer treatment,S-phase kinase-associated protein 2,inhibitor,E3 ubiquitin ligase,SCFSkp2
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要